CFO, Atrin Pharmaceuticals
Bernard C. Rudnick, chief financial officer and board director of Atrin Pharmaceuticals, is founder and managing partner of CapGenic Advisors LLC and a member / founder of several investment groups. His last posting was Immunomic Therapeutics, another FiReStarter company, where he served as director and CFO. Immunomic Therapeutics completed a license with Astellas which resulted in the largest ($300 million) upfront payment in its class of drugs and a $90 million distribution to investors.
Bernie's entrepreneurial career spans a number of startups, three of which grew to over $50 million in revenue before liquidity events. He is a founder of one of the nation's leading entrepreneurial programs (MADV) at the Fox School of Business; director of Operative Experience, Axxia Pharmaceuticals, and RSportz; and has held a number of other board positions - both commercial and not-for-profit - throughout his career. With 38 years of experience in executive-level strategy, finance, and management, Bernie has senior merger, acquisition, capital formation, and licensing leadership experience with companies ranging from startups to Fortune 50s. He has substantial experience investing and guiding investments in entrepreneurial companies and has led capital formation totaling more than $538 million and strategic and licensing transactions of over $7 billion in the past 22 years.
Bernie currently advises companies in therapeutic, medical device, and enterprise software areas. His advisory clients have included Mitsui (Mitrix), DuPont (Agri-chemical), McKesson Bioservices (now TMO), and Kika Clinical Solutions (now IBM), as well as a number of early-stage life-sciences companies.